<DOC>
	<DOCNO>NCT03019640</DOCNO>
	<brief_summary>The goal clinical research study learn safety give immune cell call natural killer ( NK ) cell chemotherapy stem cell transplant patient non-Hodgkin 's lymphoma . Participants receive autologous stem cell transplant ( transplant participant 's bone marrow blood cell ) . NK cell may kill cancer cell remain participant 's body participant 's last chemotherapy treatment . The NK cell separate donor 's umbilical cord blood . These separate NK cell grown lab increase number NK cell give participant vein . If certain type unwanted T cell grow much , investigational device call CliniMACS system use filter unwanted T cell use magnet .</brief_summary>
	<brief_title>Cord Blood-derived NK Cells With HDC/Auto SCT MCL</brief_title>
	<detailed_description>Chemotherapy , NK , Stem Cell Infusions : In stem cell transplant , day participant receive stem cell call minus day . The day receive stem cell call Day 0 . The day receive stem cell call plus day . If participant agrees take part study , Day -13 , participant receive rituximab vein 3 hour , participant receiving . This depend disease participant . Participant admit hospital receive hydration fluid vein . On Day -12 , participant receive carmustine vein 2 hour . On Days -11 -8 , participant receive etoposide vein 3 hour cytarabine vein 1 hour . On Day -7 , participant receive melphalan vein 30 minute . Participant receive rituximab vein 3 hour , participant receiving . On Days -7 -2 participant take lenalidomide mouth 1 time day . Participant swallow lenalidomide capsule whole water time day . Participant break , chew , open capsule . If participant miss dose lenalidomide , participant take soon participant remembers day . If participant miss take participant 's dose entire day , participant take participant 's regular dose next scheduled day . Participant take double participant 's regular dose make miss dose . If participant take prescribe dose lenalidomide , participant seek emergency medical care need contact study staff right away . On Day -5 , participant receive NK cell vein 1 hour . On Day 0 , participant receive stem cell transplant vein 30-60 minute . Starting Day +5 , participant receive filgrastim ( G-CSF ) needle skin 1 time day every day participant 's white blood cell count begin recover . Filgrastim design help cell bone marrow multiply , help raise white blood cell count quickly , low fever , decrease risk infection . Participant receive standard antibiotic help low risk infection . Participant may ask study staff information drug give risk . Study Visits : Before participant start treatment , follow tests/procedures perform do within last 30 day : - Blood ( 2 tablespoon ) draw check status disease check infectious disease , HIV hepatitis . Within 10-14 day lenalidomide prescribe , within 24 hour lenalidomide prescribe , participant blood pregnancy test participant become pregnant . These blood test part routine blood draw . Participant must fill lenalidomide prescription within 7 day prescribe . To take part study , participant pregnant . - Urine collect routine test . - Participant EKG either echocardiogram ( ECHO ) MUGA scan check participant 's heart function . - Participant scan check status disease . This include series x-ray ( bone survey ) chest x-ray , PET/CT scan . If participant 's doctor think need , participant also MRIs brain . - Participant lung function test . - Participant bone marrow aspiration biopsy check status disease . To collect bone marrow aspiration , area hip site numb anesthetic , small amount bone bone marrow withdrawn large needle . Up twice week Day -4 Day +7 , blood ( 2 tablespoon ) draw check donor NK cell , one first 12 participant enrol study . If donor NK cell find , blood ( 2 tablespoon ) draw 1 time week around Day +30 ( +/-3 day ) . From 30 100 day stem cell transplant , blood drawn participant NK cell blood last blood draw participant routine follow-up visit . At visit NK cell infusion Day -5 , often participant 's study doctor think need , participant check possible reaction transplant study drug , include graft versus host disease ( GVHD ) . GVHD condition transplant tissue attack transplant recipient 's body . Graft failure occur transplanted stem cell may able grow multiply participant 's body . If happens , high risk infection and/or bleed . If number white blood cell get back high enough level within 3 week transplant , stem cell may need give . The study doctor discus participant . Long-Term Follow-Up : About 28 day participant 's last lenalidomide dose , participant become pregnant , participant pregnancy test . This blood test part blood draw part standard care . At 30 100 day stem cell transplant : - Participant PET/CT and/or CT scan check status disease . - If participant 's study doctor think need , participant bone marrow aspiration biopsy check status disease . As often doctor think need Day 100 , blood ( 4 teaspoon ) and/or urine collect routine test . Length Study : Participant remain study 100 day stem cell transplant . Participation study participant complete long-term follow-up visit . This investigational study . The way researcher process NK cell investigational . It currently use research purpose . The combination stem cell transplant study drug FDA approve commercially available give patient non-Hodgkin 's lymphoma . The study doctor explain study therapy design work . Up 40 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Age 1570 2 . Patients Bcell lymphoma candidate autologous stemcell transplantation : 2 . 1 . Primary refractory relapse diffuse large Bcell lymphoma response salvage treatment . 2.2 . Primary refractory relapse follicular lymphoma indolent Bcell histology response salvage treatment . 2.3 . Chemosensitive mantlecell lymphoma first later line treatment . 3 . Adequate renal function , define estimate serum creatinine clearance &gt; /= 50 ml/min and/or serum creatinine &lt; /= 1.8 mg/dL . 4 . Adequate hepatic function ( SGOT and/or SGPT &lt; /= 3 x ULN ; bilirubin ALP &lt; /= 2 x ULN . 5 . Adequate pulmonary function FEV1 , FVC DLCO ( correct Hgb ) &gt; /= 50 % . 6 . Adequate cardiac function leave ventricular ejection fraction &gt; /= 40 % . No uncontrolled arrhythmias symptomatic cardiac disease . 7 . Patients must cord blood unit available match patient 4 , 5 , 6/6 HLA class I ( serological ) II ( molecular ) antigens . 8 . Performance status &lt; 2 ( ECOG ) . 9 . Negative Beta HCG woman childbearing potential . 1 . Primary CNS lymphoma . 2 . Grade &gt; /= 3 nonhematologic toxicity prior therapy resolve &lt; /= G1 . 3 . Prior whole brain irradiation . 4 . Active hepatitis B , either active carrier ( HBsAg + ) viremic ( HBV DNA &gt; /= 10,000 copies/mL , &gt; /= 2,000 IU/mL ) . 5 . Evidence either cirrhosis stage 34 liver fibrosis patient chronic hepatitis C positive hepatitis C serology . 6 . Active infection require parenteral antibiotic . 7 . HIV infection . 8 . Radiation therapy month prior enroll .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>B-Cell Non-Hodgkin Lymphoma</keyword>
	<keyword>Relapsed follicular lymphoma</keyword>
	<keyword>Indolent B-cell histology</keyword>
	<keyword>Natural killer cell</keyword>
	<keyword>NK</keyword>
	<keyword>Stem cell transplant</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Carmustine</keyword>
	<keyword>BCNU</keyword>
	<keyword>BiCNU</keyword>
	<keyword>Etoposide</keyword>
	<keyword>VePesid</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Ara-C</keyword>
	<keyword>Cytosar</keyword>
	<keyword>DepoCyt</keyword>
	<keyword>Cytosine arabinosine hydrochloride</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Alkeran</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>CC-5013</keyword>
	<keyword>Revlimid</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Neupogen</keyword>
</DOC>